https://www.selleckchem.com/CDK.html
g., 3.0 ± 2.7 Gy/GBq (range 0.5 - 10.6) in bone metastases. No grade (G) 4 adverse events were observed. G3 events occurred in 3 patients - 1 pancytopenia, 1 leukocytopenia and 1 pain flare-up; 3 patients reported pain-response. Conclusion 177Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well-tolerated with acceptable side effects and demonstrated long retention of the radiopeptide. Prospective clinical studies are warranted.Spontaneous mutations can alter tissue dynamics and lead to cancer initiation. Although large-scale
Like
Comment
Share
